Characterisation of seven medications approved for attention-deficit/hyperactivity disorder using <i>in vitro</i> models of hepatic metabolism-Reference-Cited by-同舟云学术

Characterisation of seven medications approved for attention-deficit/hyperactivity disorder using in vitro models of hepatic metabolism

Published:2022-07-03 Issue:7 Volume:52 Page:676-686
ISSN:0049-8254
Container-title:Xenobiotica
language:en
Short-container-title:Xenobiotica

Author:

Law Rebecca¹,Lewis David¹,Hain Daniel¹,Daut Rachel¹,DelBello Melissa P.²,Frazier Jean A.³^ORCID,Newcorn Jeffrey H.⁴,Nurmi Erika⁵,Cogan Elizabeth S.⁶,Wagner Susanne⁶,Johnson Holly¹,Lanchbury Jerry⁶

Affiliation:

1. Myriad Neuroscience, Mason, OH, USA

2. Department of Psychiatry and Behavioral Neuroscience, College of Medicine, University of Cincinnati, Cincinnati, OH, USA

3. Eunice Kennedy Shriver Center, University of Massachusetts Chan Medical School, Worcester, MA, USA

4. Icahn School of Medicine at Mount Sinai, New York, NY, USA

5. Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA, USA

6. Myriad Genetics, Salt Lake City, UT, USA

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00498254.2022.2141151

Reference38 articles.

1. Adderall. 2021. [package insert]. Ontario, Canada: Takeda Canada Inc.

2. Stability of Methylphenidate under Various pH Conditions in the Presence or Absence of Gut Microbiota

3. Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives

4. The relation between blood levels and urinary excretion of amphetamine under controlled acidic and under fluctuating urinary pH values using [14C]amphetamine

5. The Disposition and Metabolism of I.C.I. 58,834 (Viloxazine) in Humans